ArticleArchives of toxicology2025
Long-term TCDD oral exposure changes gut microbial glycosylation patterns in female but not male C57BL/6 mice.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) at high doses damages the liver and disrupts gut microbiota in mice. We investigated whether very low TCDD doses also cause dysbiosis and if sex-specific differences exist. Male and female C57BL/6 mice received 1 µg TCDD/kg body weight initially and maintenance doses biweekly for 12 weeks; controls received DMSO/corn oil. Fecal pellets were collected throughout, and cecal, liver, and gut samples at euthanasia. Mice did not suffer weight loss, and the liver weight to body weight ratio remained normal in all groups. Barrier genes' expression was unaffected in all groups. 16S sequencing of fecal pellets revealed an increase in α-diversity over the 12-week treatment period, regardless of TCDD exposure or sex. No significant differences in α-diversity were observed between control and TCDD-treated groups. Analysis of β-diversity indicated differences in microbiota composition between male and female mice, as well as over time. However, probably due to low sample numbers, we could not detect significant differences using UniFrac or other ß-diversity metrics. However, our flow cytometry-based analysis tool, FlowSoFine™, identified significantly distinct microbial signatures in TCDD-treated female mice compared to control females. We hypothesized that this could be due to the formation of bacterial clusters or to different glycosylation patterns, both undetectable by sequencing. We therefore stained the cecal material with a panel of seven fluorescent lectins, which detect typical bacterial sugar structures, i.e., glycans. Significant changes were detected for concanavalin A, soybean agglutinin, and Dolichos biflorus agglutinin binding in the gut microbiota in female but not in male mice. We isolated bacteria by fluorescence-activated cell sorting (FACS), which differed between TCDD-treated and control female mice. 16S sequencing of these bacteria revealed a high frequency of Lachnospiraceae and reduced amount of Lactobacillaceae, CAG-508, and Oscillospiraceae in the TCDD-exposed samples. Glycoconjugates govern biofilm formation, infectious behavior of bacteria, and host immune responses, but little is known about diet or xenobiotic induced changes in glycosylation. We conclude that assessing glycosylation parameters in studies of dysbiosis is relevant, as well as stratifying for sex-specific differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.